Autobahn Therapeutics rakes in $76m Series B

San Diego-based Autobahn Therapeutics, a creator of regenerative medicines for people affected by CNS disorders, has raised $76 million in Series B funding.

San Diego-based Autobahn Therapeutics, a creator of regenerative medicines for people affected by CNS disorders, has raised $76 million in Series B funding. ARCH Venture Partners and Cowen Healthcare Investments led the round with participation from BVF Partners L.P., Biogen, Bristol Myers Squibb, Pfizer Ventures, Invus, Section 32, Samsara BioCapital and Alexandria Venture Investments.

Source: Press Release